Session: 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster III
Hematology Disease Topics & Pathways:
Research, Biological therapies, Antibody Therapy, Translational Research, Non-Biological therapies, Chemotherapy, Combination therapy, Therapies, emerging technologies, Technology and Procedures, profiling, machine learning, omics technologies
At OncoPrecision, we have developed a personalized ex-vivo platform that mimics the tumor microenvironment and promotes the survival of Patient-Derived Cells (PDCs), with the goal to predict the performance of the complete array of FDA-approved drugs, as well as experimental treatments, within 7 days. This technology, which we have named Patient Micro Avatars (PMAs), consists of the co-culture of PDCs with engineered neoplastic (System Control) and stromal (Tox Control) heterologous cells in combination with a multi-tagging approach coupled to high-throughput flow cytometry (Figure: Upper Panel). Our PMAs not only enable us to rank the activity of all approved treatments, but also unveil potential unspecific toxicities of novel treatments on non-tumoral cells, thus unlocking unique insights for early drug development programs.
In this work, we introduce our PMA technology for MM by presenting differential response between patients in a Clinical Study performed in collaboration with two healthcare centers which, through approved IRBs, have provided MM patient samples from bone marrow aspiration. We present ex-vivo profiling results with a comprehensive MM drug matrix which includes SoC treatments used in several lines of therapy. We illustrate the potential of PMAs to identify differential activity from individual agents and synergistic drugs combinations in 13 patients (Figure: Lower Panel). By anticipating vulnerability/resistance to SoC treatments, our platform has the potential to become a first-in-class phenotypic biomarker to serve as a decision-support tool for Physicians to select optimal therapeutic regimes, as well as to elucidate valuable pre-clinical patient-derived insights for the development of innovative therapies for MM.
Disclosures: Marin: OncoPrecision: Current Employment. Nicola: OncoPrecision: Consultancy, Honoraria. Andino: OncoPrecision: Consultancy, Ended employment in the past 24 months, Honoraria. Bernaschini: OncoPrecision: Consultancy, Ended employment in the past 24 months. Conrrero: OncoPrecision: Current Employment. Ferreira: OncoPrecision: Current Employment. Piaggio: OncoPrecision: Current Employment. Zaki: OncoPrecision: Current Employment, Current equity holder in private company, Current holder of stock options in a privately-held company. Llorens: OncoPrecision: Current Employment, Current equity holder in private company. Gatti: OncoPrecision: Current Employment, Current equity holder in private company. Arroyo: OncoPrecision: Current Employment, Current holder of stock options in a privately-held company. Soria: OncoPrecision: Current Employment, Current holder of stock options in a privately-held company.